The safety of three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection in china

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028997

Enrollment

Unknown

Registered

2020-01-11

Start date

2020-01-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The latent tuberculosis infection

Interventions

Case series:isoniazid and rifapentine

Eligibility

Sex/Gender

All

Age

2 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. aged >2 years old; 2. Latent tuberculosis infection (positive IFN - gama release test or tuberculin test) or contact history of tuberculosis patients younger than 5 years old with bacteriological confirmation;

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women or pregnant women; 2. Bacteriological diagnosis of tuberculosis or clinical diagnosis of tuberculosis; 3. The number of leukocytes in peripheral blood was less than 2.0 * 10^9/L; 4. Weight 1.5 times of the upper limit of normal value, or bilirubin > 1.5 times of the upper limit of normal value, or symptoms and signs of liver function damage; 9. HIV patients; 10. Do not take isoniazid or rifapentine.

Design outcomes

Primary

Measure	Time frame
safety;completion rate;	—

Countries

China

Contacts

Public ContactLI Tao

Shanghai Public Health Clinical Center Affiliated to Fudan University

litao@shphc.org.cn+86 13816829726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026